☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
dravet syndrome
Zogenix Presents Results of Fintepla's (fenfluramine) Study Highlighting the Impact of Treatment on Dravet Syndrome Patients- Care...
April 19, 2021
Takeda Signs an Exclusive License Agreement with Ovid for Soticlestat to Treat Dravet Syndrome and Lennox-Gastaut Syndrome
March 4, 2021
PharmaShots Interview: Zogenix's Bradley Galer Shares Insight on Fintepla (fenfluramine, oral solution)
February 16, 2021
Takeda and Ovid Report Results of Soticlestat (TAK-935/OV935) in P-II ELEKTRA Study for Dravet Syndrome or Lennox-Gastaut Syndrome
August 26, 2020
Zogenix Reports the US FDA Acceptance of NDA and Granted Priority Review for Fintepla (fenfluramine) to Treat Dravet Syndrome
November 26, 2019
Stoke Therapeutics' STK-001 Receives FDA's Orphan Drug Designation for Dravet Syndrome
August 8, 2019
Load more...
Back to Home
Modal title
×
Modal body text goes here.